Coherus BioSciences, Inc., has announced that its United States manufacturing and distribution is well positioned to
ensure uninterrupted availability of Udenyca^® (pegfilgrastim-cbqv) for patients. Coherus does not source active pharmaceutical ingredients for Udenyca^® from China, or India, and its manufacturing site in Boulder, Colorado has not been impacted by coronavirus, the company said in a statement.

Read the company statement.

Posted 3/11/2020